Vaccines

PUBLISHER: Market Research Future | PRODUCT CODE: 1699230

PUBLISHER: Market Research Future | PRODUCT CODE: 1699230

Report Information on Middle East & Africa Human Vaccine Market Research by Vaccine Type, by Age Group, by Indication, by Administration, by Distribution Channel Forecast to 2032

PUBLISHED: February 20, 2025

PAGES: 182 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Report Information on Middle East & Africa Human Vaccine Market Research by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032

Overview of the Market

The human vaccine market in the Middle East and Africa is expected to increase at a strong compound annual growth rate (CAGR) of 8.80% over the course of the study period. Biological preparations called human vaccinations protect people from illness and its potentially serious effects by stimulating the immune system to create immunity to a particular disease. These vaccinations usually contain pathogens (such bacteria or viruses), their toxins, or surface proteins that have been attenuated or rendered inactive. This stimulates the immune system without causing the disease.

The Middle East and Africa's human vaccine market is expanding due to factors such the increase in disease load and epidemic outbreaks, as well as increased awareness of the importance of immunization in preventing infectious illnesses. Additionally, as funding and investment in expansion continue to expand, the sector will create prospects for future development.

Perspectives on Market Segments

The market for human vaccines in the Middle East and Africa has been divided into four segments: recombinant DNA, conjugate and subunit, toxoid, and inactivated.The type of vaccine is the basis for this organization.

Based on age, the market has been divided into two segments: adults and pediatrics. The pediatrics segment grew at the fastest rate during the projection period and held the greatest market share in 2023.

Based on indication, the human vaccine market in the Middle East and Africa has been divided into several segments, including polio, DTP, influenza, hepatitis, and pneumococcal.

Based on the route of administration, the market has been divided into three segments: injectable, oral, and other.

Depending on the distribution mechanism, the market has been split into public and private sectors.

The market was valued at USD Egypt million in 2023. The United Arab Emirates (UAE), Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the Rest of the Middle East are the subregions that make up the Middle East.

Due to increased government support for vaccination, rising healthcare costs, and growing awareness of the need of immunization, the Middle Eastern human vaccine market is expected to rise significantly. In April 2024, the Kingdom of Saudi Arabia pledged $500 million to the Global Polio Eradication Initiative (GPEI) over a five-year term. The launch of novel vaccinations that target a wider range of diseases and developments in vaccine technology also contribute to the market's growth. To combat the rise of infectious diseases, current trends point to a shift to customized vaccinations and more funding for research and development.

Key Players

The main players in the Middle East human vaccine market are Pfizer Inc., Vacsera, Merck & Co., Inc., AstraZeneca, SaudiVax, Cipla, GSK Plc, Sanofi, Biovac, and Bharat Biotech.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
3.10

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION IN PREVENTING INFECTIOUS DISEASES
- 4.2.2 RISING DISEASE BURDEN AND EPIDEMIC OUTBREAKS
- 4.2.3 RISING STRATEGIC INITIATIVES ASSOCIATED WITH VACCINE IN MIDDLE EAST & AFRICA
4.3 RESTRAINTS
- 4.3.1 STRINGENT REGULATORY POLICIES
4.4 OPPORTUNITY
- 4.4.1 INCREASING FUNDING AND INVESTMENT FOR EXPANSION

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 BARGAINING POWER OF BUYERS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA HUMAN VACCINES MARKET

6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE

6.1 OVERVIEW
6.2 INACTIVATED
6.3 TOXOID
6.4 CONJUGATE AND SUBUNIT
6.5 RECOMBINANT DNA

7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP

7.1 OVERVIEW
7.2 PEDIATRICS
7.3 ADULTS

8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION

8.1 OVERVIEW
8.2 PNEUMOCOCCAL
8.3 INFLUENZA
8.4 HEPATITIS
- 8.4.1 HEPATITIS A
- 8.4.2 HEPATITIS B
8.5 DTP
8.6 POLIO
- 8.6.1 INACTIVATED POLIO VACCINE (IPV)
- 8.6.2 ORAL POLIO VACCINE (OPV)
8.7 HUMAN PAPILLOMAVIRUS
8.8 MENINGOCOCCAL

9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW
9.2 INJECTABLE
9.3 ORAL
9.4 OTHERS

10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW
10.2 PUBLIC
10.3 PRIVATE

11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION

11.1 MIDDLE EAST
- 11.1.1 UAE
- 11.1.2 SAUDI ARABIA
- 11.1.3 ISRAEL
- 11.1.4 KUWAIT
- 11.1.5 OMAN
- 11.1.6 QATAR
- 11.1.7 EGYPT
- 11.1.8 BAHRAIN
- 11.1.9 REST OF MIDDLE EAST
11.2 AFRICA
- 11.2.1 KENYA
- 11.2.2 SOUTH AFRICA
- 11.2.3 NIGERIA
- 11.2.4 MOZAMBIQUE
- 11.2.5 TANZANIA
- 11.2.6 UGANDA
- 11.2.7 MOROCCO
- 11.2.8 REST OF AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS, 2023 (%)
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 12.6.2 AGREEMENT/COLLABORATION/PARTNERSHIP

13 COMPANY PROFILES

13.1 SANOFI
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 PRODUCTS OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
13.2 BHARAT BIOTECH
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 PRODUCTS OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 KEY STRATEGIES
13.3 PFIZER INC
- 13.3.1 COMPANY OVERVIEW
- 13.3.2 FINANCIAL OVERVIEW
- 13.3.3 PRODUCTS OFFERED
- 13.3.4 KEY DEVELOPMENTS
- 13.3.5 SWOT ANALYSIS
- 13.3.6 KEY STRATEGIES
13.4 MERCK & CO., INC.
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 PRODUCTS OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 KEY STRATEGIES
13.5 ASTRAZENECA
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 PRODUCTS OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 KEY STRATEGIES
13.6 CIPLA
- 13.6.1 COMPANY OVERVIEW
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 PRODUCTS OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 SWOT ANALYSIS
- 13.6.6 KEY STRATEGIES
13.7 SAUDIVAX
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 PRODUCTS OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 KEY STRATEGIES
13.8 GSK PLC
- 13.8.1 COMPANY OVERVIEW
- 13.8.2 FINANCIAL OVERVIEW
- 13.8.3 PRODUCT OFFERED
- 13.8.4 KEY DEVELOPMENTS
- 13.8.5 SWOT ANALYSIS
- 13.8.6 KEY STRATEGIES
13.9 BIOVAC
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 PRODUCTS OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 KEY STRATEGIES
13.10 VACSERA
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL OVERVIEW
- 13.10.3 PRODUCTS OFFERED
- 13.10.4 KEY DEVELOPMENTS
- 13.10.5 KEY STRATEGIES

14 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 4 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INACTIVATED, BY REGION, 2019-2032 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR TOXOID, BY REGION, 2019-2032 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR CONJUGATE AND SUBUNIT, BY REGION, 2019-2032 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR RECOMBINANT DNA, BY REGION, 2019-2032 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PEDIATRICS, BY REGION, 2019-2032 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ADULTS, BY REGION, 2019-2032 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 13 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PNEUMOCOCCAL, BY REGION, 2019-2032 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INFLUENZA, BY REGION, 2019-2032 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY REGION, 2019-2032 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 18 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS A, BY REGION, 2019-2032 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS B, BY REGION, 2019-2032 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR DTP, BY REGION, 2019-2032 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY REGION, 2019-2032 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 24 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INACTIVATED POLIO VACCINE (IPV), BY REGION, 2019-2032 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ORAL POLIO VACCINE (OPV), BY REGION, 2019-2032 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2019-2032 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR MENINGOCOCCAL, BY REGION, 2019-2032 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INJECTABLE, BY REGION, 2019-2032 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ORAL, BY REGION, 2019-2032 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PUBLIC, BY REGION, 2019-2032 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PRIVATE, BY REGION, 2019-2032 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 36 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 37 MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION)
TABLE 38 MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME)
TABLE 39 MIDDLE EAST: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION)
TABLE 40 MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION)
TABLE 41 MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME)
TABLE 42 MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION)
TABLE 43 MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME)
TABLE 44 MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION)
TABLE 45 MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME)
TABLE 46 MIDDLE EAST: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION)
TABLE 47 MIDDLE EAST: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION)
TABLE 48 UAE: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION)
TABLE 49 UAE: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME)
TABLE 50 UAE: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION)
TABLE 51 UAE: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION)
TABLE 52 UAE: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME)
TABLE 53 UAE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION)
TABLE 54 UAE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME)
TABLE 55 UAE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION)
TABLE 56 UAE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME)
TABLE 57 UAE: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION)
TABLE 58 UAE: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION)
TABLE 59 SAUDI ARABIA: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION)
TABLE 60 SAUDI ARABIA: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME)
TABLE 61 SAUDI ARABIA: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION)
TABLE 62 SAUDI ARABIA: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION)
TABLE 63 SAUDI ARABIA: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME)
TABLE 64 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION)
TABLE 65 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME)
TABLE 66 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION)
TABLE 67 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME)
TABLE 68 SAUDI ARABIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION)
TABLE 69 SAUDI ARABIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION)
TABLE 70 ISRAEL: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION)
TABLE 71 ISRAEL: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME)
TABLE 72 ISRAEL: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION)
TABLE 73 ISRAEL: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION)
TABLE 74 ISRAEL: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME)
TABLE 75 ISRAEL: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION)
TABLE 76 ISRAEL: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME)
TABLE 77 ISRAEL: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION)
TABLE 78 ISRAEL: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME)
TABLE 79 ISRAEL: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION)
TABLE 80 ISRAEL: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION)
TABLE 81 KUWAIT: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (USD MILLION)
TABLE 82 KUWAIT: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019-2032 (VOLUME)
TABLE 83 KUWAIT: HUMAN VACCINE MARKET, BY AGE GROUP 2019-2032 (USD MILLION)
TABLE 84 KUWAIT: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (USD MILLION)
TABLE 85 KUWAIT: HUMAN VACCINE MARKET, BY INDICATION 2019-2032 (VOLUME)
TABLE 86 KUWAIT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (USD MILLION)
TABLE 87 KUWAIT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019-2032 (VOLUME)
TABLE 88 KUWAIT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (USD MILLION)
TABLE 89 KUWAIT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019-2032 (VOLUME)
TABLE 90 KUWAIT: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019-2032 (USD MILLION)
TABLE 91 KUWAIT: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019-2032 (USD MILLION)
TABLE 92 OMAN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 93 OMAN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 94 OMAN: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 95 OMAN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 96 OMAN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 97 OMAN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 98 OMAN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 99 OMAN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 100 OMAN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 101 OMAN: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 102 OMAN: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 103 QATAR: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 104 QATAR: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 105 QATAR: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 106 QATAR: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 107 QATAR: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 108 QATAR: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 109 QATAR: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 110 QATAR: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 111 QATAR: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 112 QATAR: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 113 QATAR: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 114 EGYPT: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 115 EGYPT: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 116 EGYPT: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 117 EGYPT: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 118 EGYPT: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 119 EGYPT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 120 EGYPT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 121 EGYPT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 122 EGYPT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 123 EGYPT: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 124 EGYPT: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 125 BAHRAIN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 126 BAHRAIN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 127 BAHRAIN: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 128 BAHRAIN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 129 BAHRAIN: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 130 BAHRAIN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 131 BAHRAIN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 132 BAHRAIN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 133 BAHRAIN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 134 BAHRAIN: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 135 BAHRAIN: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 136 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 137 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 138 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 139 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 140 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 141 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 142 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 143 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 144 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 145 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 146 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 147 AFRICA: HUMAN VACCINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 148 AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 149 AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 150 AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 151 AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 152 AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 153 AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 154 AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 155 AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 156 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 157 AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 158 AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 159 KENYA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 160 KENYA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 161 KENYA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 162 KENYA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 163 KENYA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 164 KENYA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 165 KENYA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 166 KENYA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 167 KENYA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 168 KENYA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 169 KENYA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 170 SOUTH AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 171 SOUTH AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 172 SOUTH AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 173 SOUTH AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 174 SOUTH AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 175 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 176 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 177 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 178 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 179 SOUTH AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 180 SOUTH AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 181 NIGERIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 182 NIGERIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 183 NIGERIA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 184 NIGERIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 185 NIGERIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 186 NIGERIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 187 NIGERIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 188 NIGERIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 189 NIGERIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 190 NIGERIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 191 NIGERIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 192 MOZAMBIQUE: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 193 MOZAMBIQUE: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 194 MOZAMBIQUE: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 195 MOZAMBIQUE: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 196 MOZAMBIQUE: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 197 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 198 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 199 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 200 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 201 MOZAMBIQUE: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 202 MOZAMBIQUE: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 203 TANZANIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 204 TANZANIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 205 TANZANIA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 206 TANZANIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 207 TANZANIA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 208 TANZANIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 209 TANZANIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 210 TANZANIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 211 TANZANIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 212 TANZANIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 213 TANZANIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 214 UGANDA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 215 UGANDA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 216 UGANDA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 217 UGANDA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 218 UGANDA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 219 UGANDA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 220 UGANDA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 221 UGANDA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 222 UGANDA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 223 UGANDA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 224 UGANDA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 225 MOROCCO: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 226 MOROCCO: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 227 MOROCCO: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 228 MOROCCO: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 229 MOROCCO: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 230 MOROCCO: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 231 MOROCCO: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 232 MOROCCO: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 233 MOROCCO: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 234 MOROCCO: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 235 MOROCCO: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 236 REST OF AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (USD MILLION)
TABLE 237 REST OF AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019-2032 (VOLUME)
TABLE 238 REST OF AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 239 REST OF AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (USD MILLION)
TABLE 240 REST OF AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019-2032 (VOLUME)
TABLE 241 REST OF AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 242 REST OF AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019-2032 (VOLUME)
TABLE 243 REST OF AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (USD MILLION)
TABLE 244 REST OF AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019-2032 (VOLUME)
TABLE 245 REST OF AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 246 REST OF AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 247 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 248 AGREEMENT/COLLABORATION/PARTNERSHIP
TABLE 249 SANOFI: PRODUCTS OFFERED
TABLE 250 SANOFI: KEY DEVELOPMENTS
TABLE 251 BHARAT BIOTECH: PRODUCT OFFERED
TABLE 252 BHARAT BIOTECH: KEY DEVELOPMENTS
TABLE 253 PFIZER INC: PRODUCT OFFERED
TABLE 254 PFIZER INC: KEY DEVELOPMENTS
TABLE 255 MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 256 ASTRAZENECA: PRODUCT OFFERED
TABLE 257 CIPLA: PRODUCTS OFFERED
TABLE 258 SAUDIVAX: PRODUCTS OFFERED
TABLE 259 GSK PLC: PRODUCTS OFFERED
TABLE 260 GSK PLC: KEY DEVELOPMMENTS
TABLE 261 BIOVAC: PRODUCTS OFFERED
TABLE 262 VACSERA: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET: STRUCTURE
FIGURE 2 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: MIDDLE EAST & AFRICA HUMAN VACCINE MARKET
FIGURE 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, VACCINE TYPE SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY TYPE, 2023 & 2032 (USD MILLION)
FIGURE 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY VACCINE TYPE, 2023
FIGURE 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, AGE-GROUP SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION)
FIGURE 11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY AGE GROUP, 2023
FIGURE 12 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, INDICATION SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 13 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2023 & 2032 (USD MILLION)
FIGURE 14 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY INDICATION, 2023
FIGURE 15 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, ROUTE OF ADMINISTRATION SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2032 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 18 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, DISTRIBUTION CHANNEL SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 19 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 21 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION, 2023 & 2032 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE, BY REGION, 2023 (% SHARE)
FIGURE 23 MIDDLE EAST MARKET ANALYSIS: HUMAN VACCINE MARKET, 2019-2032 (USD MILLION)
FIGURE 24 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 25 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2023 (% SHARE)
FIGURE 26 AFRICA MARKET ANALYSIS: DIGITAL PCR MARKET, 2019-2032 (USD MILLION)
FIGURE 27 AFRICA HUMAN VACCINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 28 AFRICA HUMAN VACCINE MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 29 MIDDLE EAST AND AFRICA HUMAN VACCINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 (%)
FIGURE 30 COMPETITOR DASHBOARD: MIDDLE EAST AND AFRICA HUMAN VACCINE MARKET
FIGURE 31 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 SANOFI: SWOT ANALYSIS
FIGURE 33 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 PFIZER INC: SWOT ANALYSIS
FIGURE 35 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 CIPLA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 CIPLA: SWOT ANALYSIS
FIGURE 39 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 GSK PLC: SWOT ANALYSIS

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ